Literature DB >> 19333230

Restoration of chemosensitivity by bortezomib: implications for refractory myeloma.

Chor Sang Chim1, Yu Yan Hwang, Clara Pang, Tony W Shek.   

Abstract

BACKGROUND: A 59-year-old woman presented to the emergency department with a left rib fracture and was diagnosed with IgA multiple myeloma. The patient underwent autologous bone-marrow transplantation, and 14 months later she developed obstructive jaundice. INVESTIGATIONS: Serum protein electrophoresis, contrast CT of thorax and abdomen, endoscopic retrograde cholangiopancreatography with endoscopic biopsy and pleural biopsy. DIAGNOSIS: Extramedullary plasmacytomas at pancreatic head and pleura. MANAGEMENT: Salvage chemotherapy regimens including bortezomib plus steroid, alkylators plus steroid, bortezomib plus anthracycline and radiotherapy, and combined bortezomib, cyclophosphamide, melphalan and steroid therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19333230     DOI: 10.1038/nrclinonc.2009.15

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  16 in total

1.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

2.  Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma.

Authors:  Richard Soutar; Helen Lucraft; Graham Jackson; Anthony Reece; Jenny Bird; Eric Low; Diana Samson
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

Review 3.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

4.  Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

Authors:  María-Victoria Mateos; José-M Hernández; Miguel-T Hernández; Norma-C Gutiérrez; Luis Palomera; Marta Fuertes; Joaquín Díaz-Mediavilla; Juan-J Lahuerta; Javier de la Rubia; María-José Terol; Ana Sureda; Joan Bargay; Paz Ribas; Felipe de Arriba; Adrian Alegre; Albert Oriol; Dolores Carrera; José García-Laraña; Ramón García-Sanz; Joan Bladé; Felipe Prósper; Gemma Mateo; Dixie-Lee Esseltine; Helgi van de Velde; Jesús-F San Miguel
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

5.  PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

Authors:  Heather E Oakervee; Rakesh Popat; Nicola Curry; Pat Smith; Curly Morris; Mary Drake; Samir Agrawal; Jim Stec; David Schenkein; Dixie-Lee Esseltine; Jamie D Cavenagh
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

6.  Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.

Authors:  Evangelos Terpos; Katayoun Rezvani; Supratik Basu; Alison E Milne; Peter E Rose; Geoffrey L Scott; Amin Rahemtulla; Diana Samson; Jane F Apperley
Journal:  Eur J Haematol       Date:  2005-11       Impact factor: 2.997

7.  Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.

Authors:  Alok C Bharti; Shishir Shishodia; James M Reuben; Donna Weber; Raymond Alexanian; Saroj Raj-Vadhan; Zeev Estrov; Moshe Talpaz; Bharat B Aggarwal
Journal:  Blood       Date:  2003-12-18       Impact factor: 22.113

8.  Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

9.  Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).

Authors:  D C Case; H L Sonneborn; S D Paul; D M Hayes; B M Dorsk; R J Carroll; L Bove
Journal:  Oncology       Date:  1985       Impact factor: 2.935

10.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

View more
  5 in total

1.  Bortezomib and restoration of chemosensitivity.

Authors:  Alessandro Gozzetti
Journal:  Nat Rev Clin Oncol       Date:  2009-11       Impact factor: 66.675

2.  Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.

Authors:  C S Chim; K Y Wong
Journal:  Bone Marrow Transplant       Date:  2014-08-18       Impact factor: 5.483

3.  Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.

Authors:  Chor Sang Chim; Albert Kwok Wai Lie; Eric Yuk Tat Chan; Herman Sung Yu Liu; Ching Wa Lau; Sze Fai Yip; Joycelyn Sim; Thomas Shek-Kong Wan; Edmond Shiu-Kwan Ma; Raymond Liang; Eric Tse; Yok-Lam Kwong
Journal:  J Hematol Oncol       Date:  2012-06-08       Impact factor: 17.388

4.  A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.

Authors:  C S Chim; A K W Lie; E Y T Chan; Y Y Leung; S C W Cheung; S Y T Chan; Raymond Liang; Y L Kwong
Journal:  Ann Hematol       Date:  2010-04-29       Impact factor: 3.673

5.  Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.

Authors:  Chor Sang Chim
Journal:  J Transl Med       Date:  2010-11-26       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.